Ann: Mundipharma licenses Starpharma's VivaGel BV, page-51

This is going to be huge in my opinion (with DEP to come).

I take you back to an article which makes some good points, particularly regarding the impact of BV.

disallowed link/investment-news/starpharmas-price-slide-doesnt-gel/99839

An excerpt -

"Even if cheaper products do appear on the shelves claiming “symptomatic relief”, the superior efficacy of VivaGel is likely to make it the category leader in a market that is worth $US1 billion a year.
This is based on my belief that BV sufferers are price insensitive given how desperate potential users will be to treat this embarrassing condition.
Chronic suffers have next to no social life as they fear leaving the house, and what’s worse, there are no effective treatments on the market to treat R-BV."